US › Healthcare

Femasys Inc (FEMY)

US · Healthcare · Medical Instruments & Supplies

$2.55+0.39%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$331,827

Revenue YoY

-18.9%

Net profit

$-4.5M

EPS

$-1.33

EPS estimate

$-1.40

Net margin

-1,346.8%

EPS came in at -1.33 against a street estimate of -1.40 — a beat of 5.0%.

Key statistics

Market cap

$23.3M

Forward P/E

0.0

P/B

5.72

Book value

$1.33

EPS (TTM)

$-2.72

52-week high

$22.20

52-week low

$2.02

50-day MA

$3.08

200-day MA

$8.49

Beta

-2.07

Analyst view

Analysts rate Femasys Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $14.33.

Shareholding

Insiders

3.85%

Institutions

47.26%

Largest institutional holders

Fund	Stake
Dauntless Investment Group, LLC	3.60%
Vanguard Capital Management, LLC	0.74%
Geode Capital Management, LLC	0.37%
Citadel Advisors Llc	0.20%
Vanguard Fiduciary Trust Co	0.15%
BlackRock Inc	0.11%
Northern Trust Corp	0.07%
EP Wealth Advisors, Inc.	0.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Femasys Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.